Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metabolic disorders
Biotech
After trimming headcount, Aardvark drops trials as wait drags on
Aardvark told investors it has no plans to resume the studies “as previously designed,” as it works to find a path forward for its stalled pipeline.
Nick Paul Taylor
Aug 12, 2026 9:03am
GSK pens $1B deal for metabolic oligonucleotide from SiranBio
May 6, 2026 8:04am
Aardvark halts obesity trials, putting entire pipeline on pause
Mar 24, 2026 4:00am
Aardvark pauses ph. 3 hunger trial over 'cardiac observations'
Mar 2, 2026 4:40am
OrsoBio hits target in midstage study for metabolic conditions
Feb 10, 2026 8:00am
With 200 JPM meetings, Novo BD head seeks out the next Metsera
Jan 27, 2026 5:25pm
